



## Living Cell Technologies Limited Company Announcement

### Results of the Annual General Meeting held on 16 November 2012

**16 November 2012: Sydney, Australia & Auckland, New Zealand. Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY)**, the following voting results in respect of the resolutions laid before Members at the Annual General Meeting of Living Cell Technologies Ltd held today are provided in accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act.

The Chairman announced that he would vote all undirected proxies in favour of all resolutions.

#### **Resolution 1: Adoption of Remuneration Report**

"That the Remuneration Report required by section 300A of the Corporations Act, as contained in the Directors' Report of the Company, for the year ended 30 June 2012 be adopted, details of which are set out in the explanatory notes to resolution 1 in the notice of meeting."

This resolution was passed unanimously on a show of hands.

Instructions in respect of the proxies were:

FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION
24,084,383	-	2,899,244	213,500

#### **Resolution 2: Re-election of Professor Robert Elliott as a Director**

"That Professor Robert Elliott, being a Director of the Company, retires by rotation in accordance with the Constitution and being eligible, offers himself for re-election, be re-elected as a Director of the Company, details of which are set out in the explanatory notes to resolution 2 in the notice of meeting."

This resolution was passed unanimously on a show of hands.

Instructions in respect of the proxies were:

FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION
26,983,627	-	-	213,500

-Ends -

For further information: [www.lctglobal.com](http://www.lctglobal.com)

<p><b>At the company:</b> Dr Andrea Grant, Managing Director Tel: +64 9 276 2690 Mobile: +64 21 469000 <a href="mailto:agrant@lctglobal.com">agrant@lctglobal.com</a></p>	<p><b>Media enquiries:</b> Sally Raudon Botica Butler Raudon Partners Tel: +64 9 303 3862 Mobile: +64 21 402 502 <a href="mailto:sallyr@botica.co.nz">sallyr@botica.co.nz</a></p>
---	---

### **About Living Cell Technologies**

Living Cell Technologies (LCT) leads the world in developing cell-based therapeutics to treat diseases with high unmet clinical need. Its proprietary cell encapsulation technology IMMUPEL™ allows for cell transplantation without the need for immunosuppressant drugs.

LCT's lead therapeutic candidate DIABECCELL® is indicated for the treatment of patients with type 1 diabetes, especially those suffering from life threatening episodes of unaware hypoglycaemia (low blood sugar), a dangerous and potentially fatal diabetes complication. DIABECCELL is currently in Phase II clinical trials in both New Zealand and Argentina.

In 2011, LCT formed a partnership with Otsuka Pharmaceutical Factory Inc (OPF) in which the joint venture Diatranz Otsuka Limited (NZ) was established. Valued at A\$50m on formation, LCT vested the DIABECCELL product and associated IP into the JV, while OPF vested A\$25m to fund the final phase of development of DIABECCELL through to market approval. Both LCT and OPF are 50:50 shareholders in the current and future value generated by DIABECCELL and the associated IP.

LCT has also developed NTCELL®, a choroid plexus cell product, to treat neurodegenerative diseases such as Parkinson's disease and stroke. NTCELL's trial results indicate potential for protecting, repairing and possibly regenerating brain tissue which would otherwise die.

LCT is incorporated in Australia. Research and development, operations and manufacturing facilities are based in New Zealand.